MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

摘要

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C;R1is-OR7,NH-SO2R8;R2is hydrogen, and where X is C or CH, R 2 may also be C1-6alkyl;R3is hydrogen,C1- 6alkyl,C1-6alkoxyC1-6alkyl,C 3- 7 cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5is halo,C1-6alkyl, hydroxy,C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl or C1-6alkyl optionally substituted with C3- 7cycloalkyl; aryl or with Het; R8is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; orC1-6optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents ; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.